Background illustration for clinical trials search

Multiple Sclerosis Clinical Trials

Browse 937 multiple sclerosis clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM)

for
AML (Acute Myeloid Leukemia), Multiple Myeloma Refractory
Location: Camden NJ
Sponsor: Roger Strair

Sex: All

Age: 18+

Code: NCT07771803

Early_phase1, Recruiting

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

for
Multiple Myeloma, Triple Negative Breast Cancer,
Location: Boston MA
Sponsor: Andrew Hantel, MD

Sex: All

Age: 18+

Code: NCT07341867

Phase1, Recruiting

Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma

for
Multiple Myeloma, Plasma Cell Leukemia
Location: Salt Lake City UT
Sponsor: University of Utah

Sex: All

Age: 18+

Code: NCT06517017

Phase2, Recruiting

A Pilot Clinical Trial Comparing Topical Fluorouracil to Fluorouracil Plus Calcipotriene Field Treatments in Patients With Multiple Actinic Keratoses

for
Multiple Actinic Keratoses
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06851507

Phase3, Recruiting

An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

for
Multiple System Atrophy
Location: New York NY, Durham NC, Boca Raton FL, Pittsburgh PA,
Sponsor: Teva Branded Pharmaceutical Products R&D LLC

Sex: All

Age: 30+

Code: NCT07197866

Phase2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment

for
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Location: Philadelphia PA
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT07463807

Phase1, Phase2, Recruiting

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

for
Relapsed or Refractory Multiple Myeloma
Location: Boston MA, New York NY, Philadelphia PA, Charlotte NC,
Sponsor: ModernaTX, Inc.

Sex: All

Age: 18+

Code: NCT07116616

Phase1, Phase2, Recruiting

ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)

for
Multiple Myeloma
Location: Miami FL
Sponsor: University of Miami

Sex: All

Age: 18+

Code: NCT06997081

Phase2, Recruiting

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

for
Multiple Myeloma
Location: Halifax, New Haven CT, Hackensack NJ, Toronto,
Sponsor: Celgene

Sex: All

Age: 18+

Code: NCT06988488

Phase1, Phase2, Recruiting

Selinexor and Backbone Treatments of Multiple Myeloma Patients

for
Multiple Myeloma
Location: Boston MA, Durham NC, Seattle WA
Sponsor: Karyopharm Therapeutics Inc

Sex: All

Age: 18+

Code: NCT02343042

Phase1, Phase2, Recruiting

CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study

for
Multiple Myeloma, Multiple Myeloma Progression,
Location: Charlotte NC
Sponsor: Wake Forest University Health Sciences

Sex: All

Age: 30+

Code: NCT06644625

Recruiting

A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)

for
Multiple System Atrophy
Location: Boston MA
Sponsor: Tiziana Life Sciences LTD

Sex: All

Age: 30 - 70+

Code: NCT06868628

Phase2, Recruiting

A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

for
High Risk Smoldering Multiple Myeloma (HR-SMM)
Location: Boston MA, New York NY, Columbus OH, Detroit MI,
Sponsor: Regeneron Pharmaceuticals

Sex: All

Age: 18+

Code: NCT07393282

Phase3, Recruiting

Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)

for
Multiple Myeloma, Multiple Myeloma in Relapse,
Location: St Louis MO
Sponsor: Washington University School of Medicine

Sex: All

Age: 18+

Code: NCT07200089

Phase1, Recruiting

A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

for
Multiple Myeloma (MM)
Location: Tamarac FL, Plantation FL, Margate FL, Jacksonville FL,
Sponsor: Shanghai Henlius Biotech

Sex: All

Age: 18+

Code: NCT07477587

Phase1, Recruiting

Horizon Two: HR NDMM (MMRC-100)

for
High Risk Newly Diagnosed Multiple Myeloma
Location: Boston MA, New York NY, Chapel Hill NC, Charlotte NC,
Sponsor: Multiple Myeloma Research Consortium

Sex: All

Age: 18+

Code: NCT07053436

Phase2, Recruiting

Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

for
Relapse Multiple Myeloma, Refractory Multiple Myeloma
Location: Madison WI
Sponsor: Natalie Callander

Sex: All

Age: 18+

Code: NCT07479979

Phase1, Phase2, Recruiting

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

for
Multiple Myeloma, Relapse Multiple Myeloma,
Location: Boston MA
Sponsor: David Avigan

Sex: All

Age: 18+

Code: NCT06799026

Phase1, Recruiting

Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma

for
Multiple Myeloma, Post Stem Cell Transplant
Location: Palo Alto CA
Sponsor: Stanford University

Sex: All

Age: 18+

Code: NCT06461988

Phase2, Recruiting

Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

for
Multiple Myeloma Refractory, Multiple Myeloma in Relapse
Location: Boston MA, Hackensack NJ, New Brunswick NJ,
Sponsor: CellCentric Ltd.

Sex: All

Age: 18+

Code: NCT07096778

Phase2, Recruiting

What is multiple sclerosis?

In MS, the immune system attacks myelin, the insulation around nerve fibers in the brain and spinal cord. Damaged spots, called lesions, slow or block nerve signals, which is why symptoms range from fatigue and numbness to vision problems and trouble walking. Symptoms and pace differ so much between people that MS is often called a disease with a thousand faces. It is not contagious, and it is not directly inherited. Worldwide about 2.9 million people live with MS, someone is diagnosed roughly every five minutes, and the average age at diagnosis is 32.

Research in this field carries one of the most striking findings in modern medicine: a 2022 study of more than 10 million US military members found that infection with the Epstein Barr virus, the common virus behind mononucleosis, raises MS risk 32 times, making it the leading suspected cause. Meanwhile treatment keeps expanding, with more than 20 approved disease modifying therapies, though the progressive forms still have almost none.

The types of MS, and why they matter for trials

Types of multiple sclerosis clinical trials

Who can participate in MS trials?

Do MS trial participants get paid?

How to enroll in a clinical trial for multiple sclerosis